nateglinide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1886 105816-04-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nateglinide
  • D-Nateglinide
  • glinate
  • glunate
  • natelide
  • senaglinide
A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.
  • Molecular weight: 317.43
  • Formula: C19H27NO3
  • CLOGP: 4.30
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 66.40
  • ALOGS: -4.57
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.36 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.32 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 13 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 16.20 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 73 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 2000 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 71.89 23.83 27 1166 38260 63449569
Blood glucose increased 43.18 23.83 24 1169 83732 63404097
Glycosylated haemoglobin increased 27.87 23.83 10 1183 12388 63475441
Hypoglycaemia 25.02 23.83 15 1178 60050 63427779

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 48.43 21.14 31 2024 101563 79640770
Lactic acidosis 47.89 21.14 27 2028 70332 79672001
Blood glucose increased 31.40 21.14 25 2030 114950 79627383

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BX03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA EPC N0000175428 Glinide
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:68612 dipeptidyl peptidase-4 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Infectious disease contraindication 40733004
Hypopituitarism contraindication 74728003 DOID:9406
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Primary adrenocortical insufficiency contraindication 373662000
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 6.46 WOMBAT-PK CHEMBL
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 4.99 WOMBAT-PK
Solute carrier family 22 member 6 Transporter Ki 5.04 CHEMBL

External reference:

IDSource
4021252 VUID
N0000148693 NUI
D01111 KEGG_DRUG
4021252 VANDF
C0903898 UMLSCUI
CHEBI:31897 CHEBI
CHEMBL249263 ChEMBL_ID
CHEMBL783 ChEMBL_ID
DB00731 DRUGBANK_ID
D000077715 MESH_DESCRIPTOR_UI
5311309 PUBCHEM_CID
6833 IUPHAR_LIGAND_ID
7594 INN_ID
41X3PWK4O2 UNII
274332 RXNORM
15875 MMSL
167424 MMSL
d04743 MMSL
009028 NDDF
134604002 SNOMEDCT_US
387070004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3354 TABLET 60 mg ORAL ANDA 26 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3354 TABLET 60 mg ORAL ANDA 26 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3355 TABLET 120 mg ORAL ANDA 26 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3355 TABLET 120 mg ORAL ANDA 26 sections
NATEGLINIDE Human Prescription Drug Label 1 16571-758 TABLET 60 mg ORAL ANDA 26 sections
NATEGLINIDE Human Prescription Drug Label 1 16571-758 TABLET 60 mg ORAL ANDA 26 sections
NATEGLINIDE Human Prescription Drug Label 1 16571-759 TABLET 120 mg ORAL ANDA 26 sections
NATEGLINIDE Human Prescription Drug Label 1 16571-759 TABLET 120 mg ORAL ANDA 26 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 42291-636 TABLET, COATED 60 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 42291-637 TABLET, COATED 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-984 TABLET, COATED 60 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-984 TABLET, COATED 60 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-985 TABLET, COATED 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-985 TABLET, COATED 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 51407-656 TABLET 60 mg ORAL ANDA 22 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 51407-657 TABLET 120 mg ORAL ANDA 22 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 54868-6255 TABLET, COATED 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-328 TABLET 60 mg ORAL ANDA 27 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-328 TABLET 60 mg ORAL ANDA 27 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-329 TABLET 120 mg ORAL ANDA 27 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-329 TABLET 120 mg ORAL ANDA 27 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-434 TABLET, COATED 60 mg ORAL ANDA 28 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-434 TABLET, COATED 60 mg ORAL ANDA 28 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-435 TABLET, COATED 120 mg ORAL ANDA 28 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-435 TABLET, COATED 120 mg ORAL ANDA 28 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-673 TABLET 60 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-673 TABLET 60 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-684 TABLET 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-684 TABLET 120 mg ORAL ANDA 24 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 64380-167 TABLET 60 mg ORAL ANDA 22 sections